New drug VT3989 takes on tough cancers in early trial
Disease control
Recruiting now
This study tests a new oral drug called VT3989, alone or with other cancer drugs, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that hasn't responded to standard treatments. The trial has two phases: first, finding the safest dose, then expandi…
Phase: PHASE1, PHASE2 • Sponsor: Vivace Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC